---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-044764"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2025-03-26T23:59:59+00:00"
generated_at: "2026-05-24T04:49:25.084270+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences FY2024 net income $7.2M; PBGENE-HBV Phase 1 shows HBsAg reduction

## Summary
- Q4 2024 net loss $17.8M ($2.22/sh) vs $16.3M loss in Q4 2023; FY2024 net income $7.2M vs FY2023 loss $61.3M.
- Cash, equivalents $108.5M at Dec 31, 2024; cash runway expected into H2 2026.
- PBGENE-HBV Phase 1 low-dose cohort (N=3) dosed; well-tolerated with no grade ≥2 AE; 2 of 3 patients showed substantial HBsAg reduction.
- Partner iECURE reported complete clinical response in first infant dosed for OTC deficiency; ECUR-506 generally well tolerated.
- Appointed Cindy Atwell as Chief Development and Business Officer and Dr. Cassie Gorsuch as Chief Scientific Officer in Jan 2025.

## SEC filing metadata
- accession: 0000950170-25-044764
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2025-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000095017025044764/0000950170-25-044764-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000095017025044764/dtil-20250326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-044764
- JSON: https://secwatch.observer/filing/0000950170-25-044764.json
- Plain text: https://secwatch.observer/filing/0000950170-25-044764.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.